SLDB — Solid Biosciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1707502 ·
Last close
$6.23
Market Cap
$695.33M
52W High
$11.45
52W Low
$4.24
ADV30
1,355,095
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -57,655,000 | -53,948,000 | 389,905,000 | 125,971,000 | 47,794,000 |
| Jun 2026 | 0 | — | -57,384,000 | -54,799,000 | 420,580,000 | 159,394,000 | 46,505,000 |
| Mar 2026 | 0 | — | -57,308,000 | -56,737,000 | 422,893,000 | 297,099,000 | 48,761,000 |
| Dec 2025 | 0 | — | -49,403,000 | -49,787,000 | 232,540,000 | 59,900,000 | 52,530,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-198,918,000
Investing CF
$-45,579,000
Financing CF
$308,526,000
CapEx
$-1,378,000
Dividends Paid
—
Buybacks
$-13,644,000
EPS Diluted TTM
$-1.74
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,123,259,000
Inventory
—
Receivables
—
ST Investments
$222,957,000
EBIT TTM
$-214,887,000
Pretax Income TTM
$-215,271,000
Interest Exp TTM
$60,000
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -179,206,000 | -174,325,000 | 232,540,000 | 52,530,000 | 180,010,000 | -156,289,000 |
| Dec 2024 | 0 | -129,728,000 | -124,697,000 | 188,662,000 | 51,416,000 | 137,246,000 | -100,012,000 |
| Dec 2023 | 0 | -104,315,000 | -96,015,000 | 164,939,000 | 38,458,000 | 126,481,000 | -94,180,000 |
| Dec 2022 | 8,094,000 | -99,274,000 | -85,981,000 | 260,252,000 | 48,586,000 | 211,666,000 | -97,977,000 |
TTM Snapshot
Revenues TTM
$9,923,000
NetIncome TTM
$-207,099,000
OpCashFlow TTM
—
Assets (Latest)
$420,580,000
Forward EPS
$-1.61
Max Pain — expiry 2026-12-18
max pain strike: $7.00 · spot: $6.35 · call oi: 1,848 · put oi: 20Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATTO | Attovia Therapeutics, Inc. | $679.29M | $14.86 | — |
| IAM | Iambic Therapeutics, Inc. | $674.04M | $14.22 | — |
| AURA | Aura Biosciences, Inc. | $744.13M | $7.15 | — |
| DBVT | DBV Technologies S.A. | $627.78M | $9.99 | — |
| GLUE | Monte Rosa Therapeutics, Inc. | $775.03M | $9.07 | — |
News headlines (Yahoo Finance, 1h cache)
Solid Biosciences Eyes FDA Fast-Track Path for Duchenne Gene Therapy, Potential 2027 Filing
2026-11-17 06:12 · Yahoo
Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
2026-11-10 13:08 · Yahoo
Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
2026-11-05 13:00 · Yahoo
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
2026-11-04 21:07 · Yahoo
Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
2026-10-26 12:00 · Yahoo
Solid Biosciences to Present Research Across Gene Therapy Development, Delivery and Manufacturing at ESGCT 2026
2026-10-20 12:00 · Yahoo
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-01 20:05 · Yahoo
Solid Biosciences to Participate at Upcoming Investor Conferences
2026-09-02 12:00 · Yahoo
Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?
2026-07-02 03:28 · Yahoo
Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
2026-06-02 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.